scholarly journals Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma

Hepatology ◽  
2015 ◽  
Vol 62 (3) ◽  
pp. 829-840 ◽  
Author(s):  
Junfang Ji ◽  
Xin Zheng ◽  
Marshonna Forgues ◽  
Taro Yamashita ◽  
Eliane L. Wauthier ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Adhesion ◽  
Epithelial Cell ◽  
Tumor Cells ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Epithelial Cell Adhesion Molecule

scholarly journals Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma

2012 ◽  
Vol 41 (6) ◽  
pp. 2150-2158 ◽  
Author(s):  
JUN SANG BAE ◽  
SANG JAE NOH ◽  
KYU YUN JANG ◽  
HO SUNG PARK ◽  
MYOUNG JA CHUNG ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Adhesion ◽  
Epithelial Cell ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Dysplastic Nodule ◽  
Epithelial Cell Adhesion Molecule

scholarly journals Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Leonardo do Prado Lima ◽  
Carla Jorge Machado ◽  
João Bernardo Sancio Rocha Rodrigues ◽  
Leonardo de Souza Vasconcellos ◽  
Eduardo Paulino Junior ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Adhesion ◽  
Epithelial Cell ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Univariate Analysis ◽  
Alpha Fetoprotein ◽  
Epithelial Cell Adhesion Molecule ◽  
Number Of Patients ◽  
Significant Difference

Background and Aim. The epithelial cell adhesion molecule (EpCAM) has been proposed as a marker for cancer stem cells in human hepatocellular carcinoma (HCC) as well as in the development of novel target therapies. This study aimed to investigate the immunohistochemical expression of EpCAM and alpha-fetoprotein (AFP) in HCC patients and their association with clinicopathological characteristics. Methods. This study included Child-Pugh A HCC patients undergoing curative surgical resection. Results. A significant difference was observed in the ratio between the different phenotypes (p = 0.002), identifying 12 (29.3%) EPCAM positive tumors and 29 (70.7%) negative tumors. EpCAM+ expression was associated with AFP + (OR = 12.5, 95% CI, 1.9-84.1, p<0.001). In univariate analysis, a significant association was observed between AFP+ and EPCAM+ and the serum AFP level. A diameter of ≤ 5 cm was associated with EPCAM+, while angiolymphatic invasion was associated with APF+. In a multivariate analysis, only tumors of ≤ 5 cm were significantly associated with EpCAM+ (OR = 8.7; 95%CI, 1.27-100.0; p = 0.022). The overall survival rate was 74.9%, 69.4%, 69.4%, and 53.5% at 12, 24, 36, and 48 months, respectively. Conclusion. A considerable number of patients with EpCAM+ HCC would benefit from a specific target therapy.

Sign in / Sign up

Export Citation Format

Share Document